Company,Market Share,Strengths,Vulnerabilities,Opportunity Gap
Allergan (AbbVie),25-30%,"Brand recognition, Botox dominance","High pricing, limited innovation",Next-gen formulations
Galderma,20-25%,"Strong HA portfolio, medical credibility",Conservative approach,Digital integration
Merz Aesthetics,15-20%,Biostimulator leadership,Limited geographic presence,Emerging markets
Emerging Players,25-30%,"Price competitiveness, agility",Limited clinical data,Premium positioning
